Mesenteric and renal vascular effects of diadenosine polyphosphates (APnA)

Cardiovascular Research

Volumn 56, Issue 1, 2002, Pages 22-32

  Gabriëls, Gert ^a   Rahn, Karl Heinz ^a   Schlatter, Eberhard ^a   Steinmetz, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Adenosine; Arteries; Hemodynamics; Microcirculation

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CATECHOLAMINE; DIADENOSINE POLYPHOSPHATE; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR; RIBOSE;

ADRENAL MEDULLA; BLOOD PRESSURE; BLOOD VESSEL; BLOOD VESSEL TONE; CELL TYPE; HEART OUTPUT; HUMAN; HYPOTENSION; KIDNEY CIRCULATION; MESENTERY; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; THROMBOCYTE; VASODILATATION;

ANIMALS; DINUCLEOSIDE PHOSPHATES; FOREARM; HEMODYNAMIC PROCESSES; HUMANS; MESENTERIC ARTERIES; MICROCIRCULATION; MUSCLE, SMOOTH, VASCULAR; PERFUSION; RABBITS; RATS; RECEPTORS, PURINERGIC P2; RENAL ARTERY; VASODILATOR AGENTS;

EID: 0036776206     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00533-3     Document Type: Review

References (65)

1. Reiss J.R., Moffatt J.G. Dismutation reactions of nucleoside polyphosphates. 3. The synthesis of alpha, omega-dinucleoside 5′-polyphosphates. J Org Chem. 30:1965;3381-3387.
2. Zamecnik P.C., Stephenson M.L., Janeway C.M., Randerath K. Enzymatic synthesis of diadenosine tetraphosphate and diadenosine triphosphate with a purified lysyl-sRNA synthetase. Biochem Biophys Res Commun. 24:1966;91-97.
3. Rapaport E., Zamecnik P.C. Presence of diadenosine 5′,5‴-P1, P4-tetraphosphate (Ap4A) in mammalian cells in levels varying widely with proliferative activity of the tissue: a possible positive 'pleiotypic activator'. Proc Natl Acad Sci USA. 73:1976;3984-3988.
4. Lüthje J., Ogilvie A. The presence of diadenosine 5′,5‴-P1,P3-triphosphate (Ap3A) in human platelets. Biochem Biophys Res Commun. 115:1983;253-260.
5. Flodgaard H., Klenow H. Abundant amounts of diadenosine 5′,5‴-P1,P4-tetraphosphate are present and releasable, but metabolically inactive, in human platelets. Biochem J. 208:1982;737-742.
6. Schlüter H., Offers E., Bruggemann G., et al. Diadenosine phosphates and the physiological control of blood pressure. Nature. 367:1994;186-188.
7. Zamecnik P.C., Stephenson M.L. Nucleoside pyrophosphate compounds related to the first step in protein synthesis. Kalcher H.M., Klenow H., Munchn-Patersong G., Ottesen M., Thaysen J.H., The role of nucleotides for the function and conformation in enzymes. Alfren Benzon Symposion I. 1969;276-291 Munksguard, Copenhagen.
8. Sillero M.A., Del Valle M., Zaera E., et al. Diadenosine 5′,5″-P1,P4-tetraphosphate (Ap4A), ATP and catecholamine content in bovine adrenal medulla, chromaffin granules and chromaffin cells. Biochimie. 76:1994;404-409.
9. Lüthje J., Ogilvie A. Catabolism of Ap4A and Ap3A in whole blood. The dinucleotides are long-lived signal molecules in the blood ending up as intracellular ATP in the erythrocytes. Eur J Biochem. 173:1988;241-245.
10. Lüthje J. Origin, metabolism and function of extracellular adenine nucleotides in the blood. Klin Wochenschr. 67:1989;317-327.
11. Ogilvie A., Bläsius R., Schulze-Lohoff E., Sterzel R.B. Adenine dinucleotides: a novel class of signalling molecules. J Auton Pharmacol. 16:1996;325-328.
12. Ralevic V., Hoyle C.H., Burnstock G. Pivotal role of phosphate chain length in vasoconstrictor versus vasodilator actions of adenine dinucleotides in rat mesenteric arteries. J Physiol (Lond). 483:(Pt 3):1995;703-713.
13. Steinmetz M., Schlatter E., Boudier H.A., Rahn K.H., De Mey J.G. Diadenosine polyphosphates cause contraction and relaxation in isolated rat resistance arteries. J Pharmacol Exp Ther. 294:2000;1175-1181.
14. Ogilvie A. Extracellular functions for Ap4A. McLennan A.G., Ap4A and other dinucleotide polyphosphates. 1992;229-273 CRC Press, Boca Raton.
15. Jankowski J., Hagemann J., Tepel M., et al. Dinucleotides as growth-promoting extracellular mediators. Presence of dinucleoside diphosphates Ap2A, Ap2G, and Gp2G in releasable granules of platelets. J Biol Chem. 276:2001;8904-8909.
16. Jankowski J., Hagemann J., Yoon M.S., et al. Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int. 59:2001;1134-1141.
17. Lewis C.J., Gitterman D.P., Schluter H., Evans R.J. Effects of diadenosine polyphosphates (Ap(n)As) and adenosine polyphospho guanosines (Ap(n)Gs) on rat mesenteric artery P2X receptor ion channels. Br J Pharmacol. 129:2000;124-130.
18. Ralevic V., Jankowski J., Schluter H. Structure-activity relationships of diadenosine polyphosphates (Ap(n)As), adenosine polyphospho guanosines (Ap(n)Gs) and guanosine polyphospho guanosines (Gp(n)Gs) at P2 receptors in the rat mesenteric arterial bed. Br J Pharmacol. 134:2001;1073-1083.
19. Bo X., Fischer B., Maillard M., Jacobson K.A., Burnstock G. Comparative studies on the affinities of ATP derivatives for P2x-purinoceptors in rat urinary bladder. Br J Pharmacol. 112:1994;1151-1159.
20. Neely C.F., Matot I., Batra V.K., Bo X., Burnstock G. P2X purinoceptors in the feline pulmonary vascular bed: distribution and selective in vivo pharmacological probes. Am J Physiol. 270:1996;L889-L897.
21. Schafer R., Reiser G. Characterization of [35S]-ATP alpha S and [3H]-alpha,beta-MeATP binding sites in rat brain cortical synaptosomes: regulation of ligand binding by divalent cations. Br J Pharmacol. 121:1997;913-922.
22. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 50:1998;413-492.
23. Pohl U., Ogilvie A., Lamontagne D., Busse R. Potent effects of AP3A and AP4A on coronary resistance and autacoid release of intact rabbit hearts. Am J Physiol. 260:1991;H1692-H1697.
24. Schlatter E., Gonska T., Windau J., Mehrens T. Diadenosine polyphosphates activate a Ca(2+)-dependent K(+)-conductance in porcine aortic smooth muscle cells via P2-purinoceptors. Cell Physiol Biochem. 10:2000;125-134.
25. Hilderman R.H., Martin M., Zimmerman J.K., Pivorun E.B. Identification of a unique membrane receptor for adenosine 5′,5‴-P1,P4-tetraphosphate. J Biol Chem. 266:1991;6915-6918.
26. Flores N.A., Stavrou B.M., Sheridan D.J. The effects of diadenosine polyphosphates on the cardiovascular system. Cardiovasc Res. 42:1999;15-26.
27. van der Giet M., Khattab M., Borgel J., Schluter H., Zidek W. Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney. Br J Pharmacol. 120:1997;1453-1460.
28. Gabriëls G., Endlich K., Rahn K.H., Schlatter E., Steinhausen M. In vivo effects of diadenosine polyphosphates on rat renal microcirculation. Kidney Int. 57:2000;2476-2484.
29. Sumiyoshi R., Nishimura J., Kawasaki J., et al. Diadenosine polyphosphates directly relax porcine coronary arterial smooth muscle. J Pharmacol Exp Ther. 283:1997;548-556.
30. Busse R., Ogilvie A., Pohl U. Vasomotor activity of diadenosine triphosphate and diadenosine tetraphosphate in isolated arteries. Am J Physiol. 254:1988;H828-H832.
31. Kikuta Y., Ohiwa E., Okada K., Watanabe A., Haruki S. Clinical application of diadenosine tetraphosphate (Ap4A:F-1500) for controlled hypotension. Acta Anaesthesiol Scand. 43:1999;82-86.
32. Steinmetz M., Le T.V., Hollah P., et al. Influence of purinoceptor antagonism on diadenosine pentaphosphate-induced hypotension in anesthetized rats. J Pharmacol Exp Ther. 294:2000;963-968.
33. Khattab M., Hohage H., Hollah P., Rahn K.H., Schlatter E. Effects of diadenosine polyphosphates on systemic and regional hemodynamics in anesthetized rats. Kidney Blood Press Res. 21:1998;42-49.
34. Vigne P., Pacaud P., Loirand G., Breittmayer J.P., Frelin C. PPADS inhibits P2Y1 purinoceptors in rat brain capillary endothelial cells and in rat ileal myocytes by an indirect mechanism. Biochem Biophys Res Commun. 244:1998;332-335.
35. van Ginneken E, Rongen GA, Russel F, Smits P. Diadenosine pentaphosphate vasodilates the forearm vascular bed: Inhibition by theophylline and augmentation by pyridamole. Clin Pharmacol Ther 2002; in press.
36. Ralevic V., Burnstock G. Effects of purines and pyrimidines on the rat mesenteric arterial bed. Circ Res. 69:1991;1583-1590.
37. Bohlen H.G. Localization of vascular resistance changes during hypertension. Hypertension. 8:1986;181-183.
38. Mulvany M.J., Aalkjaer C. Structure and function of small arteries. Physiol Rev. 70:1990;921-961.
39. Lüthje J., Ogilvie A. Catabolism of Ap4A and Ap3A in human serum. Identification of isoenzymes and their partial characterization. Eur J Biochem. 169:1987;385-388.
40. Lagaud G.J., Stoclet J.C., Andriantsitohaina R. Calcium handling and purinoceptor subtypes involved in ATP-induced contraction in rat small mesenteric arteries. J Physiol (Lond). 492:(Pt 3):1996;689-703.
41. Bo X., Burnstock G. Heterogeneous distribution of [3H]alpha,beta-methylene ATP binding sites in blood vessels. J Vasc Res. 30:1993;87-101.
42. Steinmetz M., Bierer S., Hollah P., Rahn K.H., Schlatter E. Heterogenous vascular effects of AP5A in different rat resistance arteries are due to heterogenous distribution of P2X and P2Y(1) purinoceptors. J Pharmacol Exp Ther. 294:2000;1182-1187.
43. Humphrey P.P.A., Khakh B.S., Kennedy C., King B.F., Burnstock G. P2X receptors. IUPHAR Committee on receptor nomenclature and drug classification. The IUPHAR receptor compendium of receptor characterization and classification. 1998;195-208 IUPHAR Media, London.
44. Schachter J.B., Boyer J.L., Li Q., Nicholas R.A., Harden T.K. Fidelity in functional coupling of the rat P2Y1 receptor to phospholipase C. Br J Pharmacol. 122:1997;1021-1024.
45. Tepel M., Bachmann J., Schluter H., Zidek W. Diadenosine polyphosphates increase cytosolic calcium and attenuate angiotensin-II-induced changes of calcium in vascular smooth muscle cells. J Vasc Res. 33:1996;132-138.
46. Steinmetz M, Janssen A, Pelster F, Rahn KH, Schlatter E. Role of diadenosine polyphosphates in isolated human resistance arteries. Vasoactivity of diadenosine polyphosphates in human small mesenteric resistance arteries. J Pharmacol Exp Ther, submitted.
47. Abrahamson D.R., Robert B., Hyink D.P., St. John P.L., Daniel T.O. Origins and formation of microvasculature in the developing kidney. Kidney Int Suppl. 67:1998;S7-11.
48. Bianchi B.R., Lynch K.J., Touma E., Niforatos, et al. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol. 376:1999;127-138.
49. Garcia-Guzman M., Soto F., Gomez-Hernandez J.M., Lund P.E., Stuhmer W. Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue. Mol Pharmacol. 51:1997;109-118.
50. van der Giet M., Jankowski J., Schluter H., Zidek W., Tepel M. Mediation of the vasoactive properties of diadenosine tetraphosphate via various purinoceptors. J Hypertens. 16:1998;1939-1943.
51. van der Giet M., Cinkilic O., Jankowski J., et al. Evidence for two different P2X-receptors mediating vasoconstriction of Ap5A and Ap6A in the isolated perfused rat kidney. Br J Pharmacol. 127:1999;1463-1469.
52. van der Giet M., Westhoff T., Cinkilic O., et al. The critical role of adenosine and guanosine in the affinity of dinucleoside polyphosphates to P(2X)-receptors in the isolated perfused rat kidney. Br J Pharmacol. 132:2001;467-474.
53. Inscho E.W., Mitchell K.D., Navar L.G. Extracellular ATP in the regulation of renal microvascular function. FASEB J. 8:1994;319-328.
54. Inscho E.W., Ohishi K., Navar L.G. Effects of ATP on pre- and postglomerular juxtamedullary microvasculature. Am J Physiol. 263:1992;F886-F893.
55. Inscho E.W. Purinoceptor-mediated regulation of the renal microvasculature. J Auton Pharmacol. 16:1996;385-388.
56. Churchill P.C., Ellis V.R. Pharmacological characterization of the renovascular P2 purinergic receptors. J Pharmacol Exp Ther. 265:1993;334-338.
57. Eltze M., Ullrich B. Characterization of vascular P2 purinoceptors in the rat isolated perfused kidney. Eur J Pharmacol. 306:1996;139-152.
58. Inscho E.W., Cook A.K., Mui V., Miller J. Direct assessment of renal microvascular responses to P2-purinoceptor agonists. Am J Physiol. 274:1998;F718-F727.
59. 2+ concentration in endothelial cells. Cell Physiol Biochem. 8:1998;175-184.
60. Chan C.M., Unwin R.J., Bardini M., et al. Localization of P2X1 purinoceptors by autoradiography and immunohistochemistry in rat kidneys. Am J Physiol. 274:1998;F799-F804.
61. Boyer J.L., Romero-Avila T., Schachter J.B., Harden T.K. Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol. 50:1996;1323-1329.
62. Bültmann R., Tuluc F., Starke K. On the suitability of adenosine 3′-phosphate 5′-phosphosulphate as a selective P2Y receptor antagonist in intact tissues. Eur J Pharmacol. 351:1998;209-215. [corrected and republished in Eur J Pharmacol 1998 Oct 16;359(1):95-101].
63. Lambrecht G., Friebe T., Grimm U., et al. PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol. 217:1992;217-219.
64. Windscheif U., Ralevic V., Baumert H.G., et al. Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors. Br J Pharmacol. 113:1994;1015-1021.
65. Kikuta Y., Sekine A., Tezuka S., et al. Intravenous diadenosine tetraphosphate in dogs. Cardiovascular effects and influence on blood gases. Acta Anaesthesiol Scand. 38:1994;284-288.